Efferon Develops Pediatric Sepsis Device to Reduce Childhood Mortality
Efferon is working on reducing the high mortality rate of pediatric sepsis with a medical device that filters toxins and cytokines from children's blood. The startup, which recently received CE mark approval in Europe for its Efferon NEO product, has deployed it across intensive care units in over 30 countries. CEO Dima Romashin explains how the technology addresses both endotoxins (the 'flame') and cytokines ('smoke'), a dual threat during sepsis that current devices often fail to manage simultaneously. Efferon's pediatric device is tailored for children’s lower blood volume, making it more effective than adult versions. The company plans to seek FDA approval in the near future and anticipates reaching $2 million in annualized revenue by 2026. Originally developed at Moscow State University, Efferon has drawn on scientific research led by co-founder Ivan Bessonov.
